Affiliation:
1. Department of Nuclear Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi
830011, Xinjiang, China
Abstract
Objective:
[18F] AV-45 can be produced in a simple, stable, and repeatable
manner on the Tracerlab FXF-N platform using a self-editing synthetic procedure and
solid-phase extraction purification method. This technique is applied to positron emission
tomography (PET) imaging of Alzheimer's disease (AD) to observe its distribution
and characteristics in various brain regions and its diagnostic efficiency for the disease.
Methods:
The precursor was subjected to nucleophilic radiofluorination at 120 °C in anhydrous
dimethyl sulfoxide, followed by acid hydrolysis of the protecting groups. The
neutralized reaction mixture was purified by solid phase extraction to obtain a relatively
pure [18F] AV-45 product with a high specific activity. A total of 10 participants who
were diagnosed with Alzheimer's disease (AD group) and 10 healthy controls (HC
group) were included retrospectively. All of them underwent [18F] AV-45 brain PET/CT
imaging. The distribution of [18F] AV-45 in the AD group was analyzed visually and
semi-quantitatively.
Results:
Six consecutive radiochemical syntheses were performed in this experiment.
The average production time of [18F] AV-45 was 52 minutes, the radiochemical yield was
14.2 % ± 2.7% (n = 6), and the radiochemical purity was greater than 95%. When used
with PET/CT imaging, the results of the visual analysis indicated increased [18F] AV-45
radioactivity uptake in the frontal, temporal, and parietal lobes in AD patients. Semiquantitative
analysis showed the highest diagnostic efficacy in the posterior cingulate
gyrus compared with other brain regions (P < 0.001).
Conclusion:
Intravenous [18F] AV-45 was successfully prepared on the Tracerlab FXF-N
platform by solid-phase extraction of crude product and automated radiochemical synthesis.
PET/CT imaging can be used to diagnose and evaluate AD patients and provide a
more robust basis for clinicians to diagnose AD.
Funder
Natural Science Foundation of Xinjiang Uygur Autonomous Region
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Reference34 articles.
1. Weidner W.S.; Barbarino P.; Thestate of the art of dementia research: New frontiers. Alzheimers Dement 2019,15(7),P1473
2. Zhang Y.L.; Hu X.L.; Li Y.H.; Zhao C.X.; International clinical practice guideline of Chinese medicine Alzheimer. World J Tradit Chin Med 2021,7,265-275
3. Levin O.S.; Vasenina E.E.; 25 Years of the amyloid hypothesis of the origin of Alzheimer’s disease: Advances, failures, and new perspectives. Neurosci Behav Physiol 2017,47(9),1065-1070
4. Litvinenko I.V.; Emelin A.Y.; Lobzin V.Y.; he amyloid hypothesis of Alzheimer’s disease: Past and present, hopes and disappointments. Neurology neuropsychiatry. Psychosomatics 2019,11(3),4-10
5. Rinne J.O.; Brooks D.J.; Rossor M.N.; Fox N.C.; Bullock R.; Klunk W.E.; Mathis C.A.; Blennow K.; Barakos J.; Okello A.A.; de LIano S.R.M.; Liu E.; Koller M.; Gregg K.M.; Schenk D.; Black R.; Grundman M.; 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: A phase 2, double-blind, placebo- controlled, ascending-dose study. Lancet Neurol 2010,9(4),363-372